Clinical trial · no report yet · Phase 1/Phase 2
WU-KONG1
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
- NCT03974022 ↗
- Active, not recruiting
- Dizal Pharmaceuticals
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 8 | |
| YouTube | 3 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Sunvozertinib
- Arms
- Part A Dose escalation · Experimental
- Part A Dose expansion cohort 1 · Experimental
- Part A Dose expansion cohort 2 · Experimental
- Part A Dose expansion cohort 3 · Experimental
- Part A Dose expansion cohort 4 · Experimental
- Part A Dose expansion cohort 5 · Experimental
- Part A Dose expansion cohort 6 · Experimental
- Part B Dose extension cohort 1 · Experimental
- Part B Dose extension cohort 2 · Experimental
- Enrollment
- 315
- Primary outcomes
- Part A Dose Escalation: Dose Limiting Toxicities (DLTs).
- Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).
- Sponsor
- Dizal Pharmaceuticals
- Start
- Jul 9, 2019
- Primary completion
- Jul 29, 2024
- Results posted
- Yes
- Registry record
- NCT03974022 · updated Jan 29, 2026
Publications
linked from the registry- Yang JC, Wang M, Doucet L, Fan Y, Lv D, Sun M, Huang D, Greillier L, Planchard D, Hong Q, Mazieres J, Felip E, Li X, Hu Y, Fang J, Bazhenova L, Ghiringhelli F, Cobo Dols MA, Rodriguez LP, Bearz A, Pellini B, Kim YJ, Bosch-Barrera J, Shim BY, Luo YH, Tiseo M, Yang TY, Carcereny E, Memmott RM, Zalcman G, de Castro Carpeno J, Di Noia V, Parra HS, Streich G, Lee DH, Shum E, Han JY, Jaime JC, Brungs D, John T, D'Arcangelo M, Joaquin AB, Liu G, Antonuzzo L, Hinojal GF, Le X, Zheng L, Janne PA; WU-KONG1B. Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). J Clin Oncol. 2025 Oct 10;43(29):3198-3208. doi: 10.1200/JCO-25-00788. Epub 2025 Sep 9. PubMed 40923280
- Miyamura BV, Mambetsariev I, Fricke J, Arias-Romero J, Cadman K, Shrestha S, Pisick E, Nguyen D, Malhotra J, Reyes A, Salgia R. Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward. Med. 2025 Sep 12;6(9):100803. doi: 10.1016/j.medj.2025.100803. Epub 2025 Aug 8. PubMed 40782807
- Luan T, Lin X, Xie X, Yang G, Wang S, Hao J, Zhou C. First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma. Anticancer Drugs. 2024 Sep 1;35(8):757-760. doi: 10.1097/CAD.0000000000001628. Epub 2024 Jun 26. PubMed 38924456